GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corium International Inc (NAS:CORI) » Definitions » Cash Flow from Financing

Corium International (Corium International) Cash Flow from Financing : $62.93 Mil (TTM As of Jun. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Corium International Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2018, Corium International paid $0.00 Mil more to buy back shares than it received from issuing new shares. It spent $0.48 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.58 Mil on other financial activities. In all, Corium International spent $0.12 Mil on financial activities for the three months ended in Jun. 2018.


Corium International Cash Flow from Financing Historical Data

The historical data trend for Corium International's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corium International Cash Flow from Financing Chart

Corium International Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17
Cash Flow from Financing
Get a 7-Day Free Trial 10.26 37.86 58.28 -0.30 57.34

Corium International Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.82 0.67 0.34 62.04 -0.12

Corium International Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Corium International's Cash from Financing for the fiscal year that ended in Sep. 2017 is calculated as:

Corium International's Cash from Financing for the quarter that ended in Jun. 2018 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $62.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corium International  (NAS:CORI) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Corium International's issuance of stock for the three months ended in Jun. 2018 was $-0.21 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Corium International's repurchase of stock for the three months ended in Jun. 2018 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Corium International's net issuance of debt for the three months ended in Jun. 2018 was $-0.48 Mil. Corium International spent $0.48 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Corium International's net issuance of preferred for the three months ended in Jun. 2018 was $0.00 Mil. Corium International paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Corium International's cash flow for dividends for the three months ended in Jun. 2018 was $0.00 Mil. Corium International received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Corium International's other financing for the three months ended in Jun. 2018 was $0.58 Mil. Corium International received $0.58 Mil on other financial activities.


Corium International Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Corium International's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Corium International (Corium International) Business Description

Traded in Other Exchanges
N/A
Address
Corium International Inc is a commercial-stage biopharmaceutical company which is focused on the development, manufacture, and commercialization of specialty pharmaceutical products. The company has multiple proprietary programs in preclinical and clinical development focusing primarily on the treatment of neurological disorders. It has few proprietary transdermal platforms such as Corplex for small molecules and MicroCor which is a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides, and proteins. The company's products include Clonidine TDS, Fentanyl TDS, and Crest Whitestrips.
Executives
Essex Woodlands Health Ventures Fund Vii Lp 10 percent owner 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Robert S Breuil officer: Chief Financial Officer 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Ronald W Eastman director, 10 percent owner 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Paul Goddard director ADOLOR CORPORATION, 700 PENNSYLVANIA DR., EXTON PA 19341
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Ivan P. Gergel director C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO CA 94158
Peter D Staple director, officer: President & CEO 863 C MITTEN ROAD, BURLINGAME CA 94010
Joseph J. Sarret officer: Chief Business Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003